Clinical Trial

Solidarity/Tokomeza Ebola Trial

Study acronym: TOKOMEZA
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The TokomezaPlus Ebola trial is a phase I/II double blind randomised clinical trial designed to assess the safety and immunogenicity of candidate SUDV vaccines in Uganda during the inter outbreak period. Uganda is prone to Ebola virus disease outbreaks especially those caused by the Ebola Sudan (SUDV) species. TokomezaPlus Ebola Vaccine trial protocol has two main components: a) Safety b) Immunogenicity and is designed to create a living protocol that will be used to study the safety and immunogenicity of SUDV-candidate vaccines in the East African EVD-prone countries.
Trial Details
NCT Number NCT05909358
Lead Sponsor Makerere University
Collaborators: Makerere University Lung Institute, MRC/UVRI and LSHTM Uganda Research Unit, Makerere University Walter Reed Program, Epicentre, Uganda Virus Research Institute-International Aids Vaccine Initiative, Ministry of Health, Uganda
Conditions Sudan Ebola Virus Vaccines
Enrollment 2,121 participants
Start Date 2023-07
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2023-06-18